Abstract 590P
Background
Approximately 30% of colorectal cancers arise from the rectum with surgical resection being the mainstay of treatment. For rectal cancers with high-risk pathological features or cases of LARC, preoperative NAT followed by total mesorectal excision +/- adjuvant therapy is recommended. However, this paradigm is associated with questionable survival benefits and high morbidity. Post-NAT and post-surgical risk stratification using ctDNA may help predict outcomes in LARC pts.
Methods
Plasma samples (n=90) from pts with LARC (N=30, median age: 67 years) were analyzed retrospectively. A tumor-informed assay (Signatera™) was used to quantify ctDNA pre-NAT, post-NAT, and post-surgery. Neoadjuvant rectal (NAR) score was calculated and compared to ctDNA status to predict recurrence risk and survival outcomes.
Results
At the pre-NAT time point, ctDNA detection rate was 90% (27/30). Pts who were ctDNA-positive either post-NAT (N=5) or post-surgery (N=3) had worse recurrence-free survival (RFS) (HR 8.4, 95%CI: 2.3-30, p<0.001 and HR 14, 95%CI: 3.1-66, p<0.001, respectively), when compared to ctDNA-negative pts. Similarly, pts with a high NAR score exhibited an inferior RFS when compared to those with a low-risk score (HR: 21, 95%CI: 2.6-2731, p=0.001). When utilized in combination with ctDNA status in the post-NAT setting, ctDNA-positive with an intermediate-high NAR score exhibited an inferior RFS compared to ctDNA-negative pts with a low NAR score (HR 33.5, 95%CI: 3.7-4419, p<0.001) with 100% recurrence rate. Likewise, post-surgery, ctDNA-positive pts with an intermediate-high NAR score exhibited an inferior RFS, with a recurrence rate of 37.5%, when compared to ctDNA-negative pts with a low NAR score, none of whom recurred (HR 75, 95%CI: 2.6-4916, p<0.001). In multivariate analysis, ctDNA status post-surgery (p=0.039) and pathological nodal status (p=0.033) were the most significant risk factors associated with recurrence.
Conclusions
Post-treatment ctDNA status either as a sole surrogate outcome measure or as an adjunct to the NAR score may predict NAT response, improve risk stratification and potentially improve outcomes in LARC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Laliotis, E. Spickard: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks/Shares: Natera, Inc. G.V. George: Financial Interests, Personal, Financially compensated role: Natera, Inc.. S. Sharma, A. Jurdi, H. Sethi: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks or ownership: Natera, Inc. M.C. Liu: Financial Interests, Personal, Full or part-time Employment: Natera, Inc.; Financial Interests, Personal, Stocks/Shares: Natera, Inc.; Financial Interests, Institutional, Research Grant: Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Financial Interests, Personal, Other: AstraZeneca, Genomic Health, Ionis; Financial Interests, Institutional, Advisory Board: AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax. G. Martinelli: Financial Interests, Institutional, Research Funding: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Genzyme, Celgene; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Genzyme, Celgene, Ariad Pharma, Roche; Financial Interests, Personal, Speaker’s Bureau: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Pfizer, Genzyme, Celgene Arida GSK; Financial Interests, Personal, Other: Novartis, Bristol Myers Squibb, Amgen, AIRC, AIL, Pfizer, Genzyme, Celgene Arida GSK. All other authors have declared no conflicts of interest.
Resources from the same session
538P - Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Presenter: Giulia Pretelli
Session: Poster session 10
539P - Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Presenter: Eduard Teixidor Vilà
Session: Poster session 10
540P - Impact of adjuvant radiotherapy (ART) on survival time in patients with hemangiopericytoma (HPC): A population study
Presenter: Tala Alshwayyat
Session: Poster session 10
541P - A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Presenter: Manuel Mazariegos Rubi
Session: Poster session 10
542P - Drug screening in Li-Fraumeni syndrome brain tumor models
Presenter: Anna Kolodziejczak
Session: Poster session 10
543P - Bevacizumab and hydroxyurea treatment in grade 2 and 3 meningioma: A monocentric experience
Presenter: Giulia Cerretti
Session: Poster session 10
544P - Clinical and molecular features of primary central nervous system tumor with Lynch syndrome
Presenter: Nan Liu
Session: Poster session 10
545P - Antibody-fragment based immunotherapeutic approaches for medulloblastoma and rhabdomyosarcoma
Presenter: Judith Niesen
Session: Poster session 10
546P - Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL)
Presenter: Alexandre Bertucci
Session: Poster session 10
547P - Clinicopathological and molecular study of embryonal tumours with multilayered rosettes
Presenter: Lianghong Teng
Session: Poster session 10